

Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region - Global Forecast to 2026

<https://marketpublishers.com/r/I23AECD7662EN.html>

Date: November 2021

Pages: 225

Price: US\$ 4,950.00 (Single User License)

ID: I23AECD7662EN

Abstracts

The global injection pens market is projected to reach USD 53.3 billion by 2026 from USD 37.6 billion in 2021, at a CAGR of 7.2% during the forecast period. Growing prevalence of chronic diseases, increasing number of regulatory approvals, favourable reimbursement and government support, and technological advancements in injection pens tend to drive the market. Though the market is growing, but factors like alternative drug delivery modes, poor reimbursement scenarios in developing regions and needle anxiety tend to restrain the market growth. Whereas, needle-stick injuries & misuse of injection pens tend to pose a challenge for the market. But, the opportunities for the market lie in the patent expiry of biologics and emerging markets.

Based on product, the disposable injection pen segment holds the largest share during the forecast period.

Based on type, the injection pens market is segmented into reusable and disposable injection pens. In 2020, the disposable injection pens segment accounted for the largest share of the global injection pens market. The large share of the disposable injection pens segment can be attributed to their ease of use and the presence of a built-in cartridge which eliminates the need for manually loading the cartridge, making it more convenient for patients with reduced dexterity or visual impairments.

Based on therapy, the diabetes segment holds the highest growth rate during the forecast period.

Based on therapy, the injection pens market is segmented into diabetes, growth hormone therapy, fertility, osteoporosis, autoimmune diseases, cancer, and other therapies. In 2020, the diabetes segment accounted for the largest share of the injection pens market. The large share of this segment is attributed to the high prevalence of diabetes, increasing awareness about insulin pens among diabetic patients, the rising geriatric population, increased patient support programs by companies & government for diabetes, and the growing availability of insulin pens in the market.

Based on diabetes therapy, the in GLP-1 segment holds the highest growth rate during the forecast period.

Based on type of diabetes therapy, the injection pens market for diabetes therapy is segmented into insulin and GLP-1. In 2020, the GLP-1 segment accounted for the highest growth rate of the injection pens market for diabetes therapy. The growth in the market can be attributed to the higher efficiency of GLP-1 to reduce the blood sugar levels.

Based on end user, the home-care settings segment holds the highest growth rate during the forecast period.

Based on end users, the injection pens market is segmented into home care settings and hospitals & clinics. In 2020, the home care settings segment accounted for the highest growth of the injection pens market. The growing geriatric population, ease of drug administration, increasing prevalence of chronic diseases, technological advancements, and favorable reimbursement scenarios are some of the key factors driving the growth rate of the home care settings market.

Asia Pacific is expected to grow at the highest rate in 2020

Asia Pacific is expected to grow at the highest rate in the forecast year. The rising geriatric population, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for advanced technologies, and expansion of private-sector hospitals to rural areas in various countries in the APAC are the major factors driving the growth of the injection pen market in this region.

Break of primary participants was as mentioned below:

By Company Type – Tier 1–60%, Tier 2–30%, and Tier 3–10%

By Designation – C-level–30%, Director-level–50%, Others–20%

By Region – North America–45%, Europe–15%, Asia Pacific–25%, Latin America- 10%, Middle East and Africa–5%

Key players in the Injection pen market

Prominent players in the injection pens market include Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), Novartis AG (Switzerland), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK), Sulzer Ltd. (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Pfizer (US), Biocon Ltd. (India), Lupin Ltd. (India), Wockhardt Ltd. (India), AptarGroup, Inc. (US), and Gerresheimer AG (Germany). The other players includes Shaily Engineering Plastics Ltd. (India), Bepak Europe Ltd. (UK), SHL Medical AG (Switzerland), Emperra GmbH (Germany), Nemera France SAS, Companion Medical, Inc. (US), and Jiangsu Delfu Medical Device Co., Ltd. (China).

Research Coverage:

The report analyzes the injection pen market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, therapy, end user, and region. The report also includes a product portfolio matrix of various injection pen products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

Market Penetration: Comprehensive information on product portfolios offered by the top players in the global injection pen market. The report analyzes this market by product type, therapy, end user and region

Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global injection pen market

Market Development: Comprehensive information on the lucrative emerging markets by product type, therapy, end user and region

Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global injection pen market

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global injection pen market.

Contents

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED FOR THE STUDY

1.3.3 CURRENCY

TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD

1.4 STAKEHOLDERS

1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

FIGURE 2 PRIMARY SOURCES

2.1.2.1 Key data from primary sources

2.1.2.2 Key industry insights

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS

2.2 MARKET SIZE ESTIMATION

FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: SANOFI

FIGURE 7 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES: INJECTION PENS MARKET (2020)

FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTION PENS MARKET (2021–2026)

FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

FIGURE 10 TOP-DOWN APPROACH

2.3 MARKET BREAKDOWN & DATA TRIANGULATION

FIGURE 11 MARKET DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ANALYSIS

2.5 ASSUMPTIONS FOR THE STUDY

2.6 RISK ASSESSMENT

TABLE 2 RISK ASSESSMENT: INJECTION PENS MARKET

2.7 LIMITATIONS

2.7.1 METHODOLOGY-RELATED LIMITATIONS

2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

FIGURE 12 INJECTION PENS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)

FIGURE 13 INJECTION PENS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)

FIGURE 14 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2021 VS. 2026 (USD MILLION)

FIGURE 15 INJECTION PENS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)

FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE INJECTION PENS MARKET

4 PREMIUM INSIGHTS

4.1 INJECTION PENS MARKET OVERVIEW

FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH

4.2 ASIA PACIFIC: INJECTION PENS MARKET, BY THERAPY AND COUNTRY (2020)

FIGURE 18 DIABETES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC INJECTION PENS MARKET IN 2020

4.3 INJECTION PENS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE INJECTION PENS MARKET DURING THE FORECAST PERIOD

4.4 INJECTION PENS MARKET, BY REGION, 2021–2026

FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL INJECTION PENS MARKET IN 2026

4.5 INJECTION PENS MARKET: DEVELOPED VS. DEVELOPING MARKETS

FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING

THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 MARKET DYNAMICS

FIGURE 22 INJECTION PENS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.1.1 MARKET DRIVERS

5.1.1.1 Growing prevalence of chronic diseases

FIGURE 23 NUMBER OF PEOPLE WITH CHRONIC DISEASES IN THE US, 1995–2030 (MILLION INDIVIDUALS)

FIGURE 24 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040 (MILLION)

FIGURE 25 GLOBAL CANCER INCIDENCE, 2015–2040 (MILLION)

5.1.1.2 Increasing number of regulatory approvals

5.1.1.3 Favorable reimbursement and government support

5.1.1.4 Technological advancements in injection pens

TABLE 3 MARKET DRIVERS: IMPACT ANALYSIS

5.1.2 MARKET RESTRAINTS

5.1.2.1 Preference for alternative drug delivery modes

5.1.2.2 Poor reimbursement scenario in developing countries

5.1.2.3 Needle anxiety

TABLE 4 MARKET RESTRAINTS: IMPACT ANALYSIS

5.1.3 MARKET OPPORTUNITIES

5.1.3.1 Patent expiry of biologics to drive the demand for biosimilars

5.1.3.2 Growth opportunities in emerging markets

FIGURE 26 DIABETES POPULATION IN DEVELOPING COUNTRIES, 2020 VS. 2040 (MILLION)

TABLE 5 RISING INCOME LEVELS IN EMERGING COUNTRIES

TABLE 6 MARKET OPPORTUNITIES: IMPACT ANALYSIS

5.1.4 MARKET CHALLENGES

5.1.4.1 Needlestick injuries and misuse of injection pens

TABLE 7 MARKET CHALLENGES: IMPACT ANALYSIS

5.2 VALUE CHAIN ANALYSIS

FIGURE 27 INJECTION PENS MARKET: VALUE CHAIN ANALYSIS

5.3 SUPPLY CHAIN ANALYSIS

FIGURE 28 INJECTION PENS MARKET: SUPPLY CHAIN ANALYSIS

5.4 PRICING ANALYSIS

TABLE 8 PRICING OF INJECTION PENS AVAILABLE IN THE MARKET

5.5 ECOSYSTEM MARKET MAP

FIGURE 29 INJECTION PENS MARKET: ECOSYSTEM MARKET MAP

5.6 PORTER'S FIVE FORCES ANALYSIS

TABLE 9 INJECTION PENS MARKET: PORTER'S FIVE FORCES ANALYSIS

5.6.1 INTENSITY OF COMPETITIVE RIVALRY

5.6.2 BARGAINING POWER OF SUPPLIERS

5.6.3 BARGAINING POWER OF BUYERS

5.6.4 THREAT OF SUBSTITUTES

5.6.5 THREAT OF NEW ENTRANTS

5.7 REGULATORY ANALYSIS

5.7.1 NORTH AMERICA

5.7.1.1 US

TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION

TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS

5.7.1.2 Canada

TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS

FIGURE 30 CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS

5.7.2 EUROPE

FIGURE 31 EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES

5.7.3 ASIA PACIFIC

5.7.3.1 Japan

TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA

5.7.3.2 China

TABLE 14 CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL

TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES

5.7.3.3 India

5.8 IMPACT OF COVID-19 ON THE INJECTION PENS MARKET

5.9 PATENT ANALYSIS

5.9.1 PATENT PUBLICATION TRENDS FOR INJECTION PENS

FIGURE 32 PATENT PUBLICATION TRENDS (JANUARY 2011–SEPTEMBER 2021)

5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS

FIGURE 33 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)

FIGURE 34 TOP APPLICANT COUNTRIES/REGIONS FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)

5.10 TECHNOLOGY ANALYSIS

TABLE 16 PEN INJECTORS CLASSIFICATION

- 5.10.1 KEY TECHNOLOGIES
 - 5.10.1.1 Dose setting and needle actuation
 - 5.10.1.2 Pen injector material
- 5.10.2 COMPLEMENTARY TECHNOLOGIES
 - 5.10.2.1 In-built dose and time log
 - 5.10.2.2 Wireless connectivity
 - 5.10.2.3 Smartpen injectors
 - 5.10.2.4 Smart caps and attachments
 - 5.10.2.5 Injector temperature monitoring
- 5.10.3 ADJACENT TECHNOLOGIES
 - 5.10.3.1 Autoinjectors
 - 5.10.3.2 Insulin pumps

6 INJECTION PENS MARKET, BY TYPE

6.1 INTRODUCTION

TABLE 17 INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

6.2 DISPOSABLE INJECTION PENS

6.2.1 HIGH PATIENT COMPLIANCE AND EASE OF HANDLING TO DRIVE THE ADOPTION OF DISPOSABLE INJECTION PENS

TABLE 18 DISPOSABLE INJECTION PENS AVAILABLE IN THE MARKET

TABLE 19 DISPOSABLE INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

6.3 REUSABLE INJECTION PENS

6.3.1 REUSABLE INJECTION PENS TO REGISTER THE HIGHEST GROWTH DUE TO TECHNOLOGICAL ADVANCEMENTS

TABLE 20 REUSABLE INJECTION PENS AVAILABLE IN THE MARKET

TABLE 21 REUSABLE INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 INJECTION PENS MARKET, BY THERAPY

7.1 INTRODUCTION

TABLE 22 INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

7.2 DIABETES

TABLE 23 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 24 INJECTION PENS MARKET FOR DIABETES THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.2.1 INSULIN

7.2.1.1 Rising prevalence of diabetes is driving the growth of this market

TABLE 25 EXAMPLES OF INSULIN INJECTION PENS

TABLE 26 INJECTION PENS MARKET FOR INSULIN THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.2.2 GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY

7.2.2.1 Strong focus of major pharmaceutical companies to introduce GLP-1 drugs to drive market growth

TABLE 27 EXAMPLES OF GLP-1 INJECTION PENS

TABLE 28 INJECTION PENS MARKET FOR GLP-1 THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.3 GROWTH HORMONE THERAPY

7.3.1 DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN THE MARKET GROWTH

TABLE 29 EXAMPLES OF INJECTION PENS FOR GROWTH HORMONE THERAPY

TABLE 30 INJECTION PENS MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.4 OSTEOPOROSIS

7.4.1 GROWING PREVALENCE OF OSTEOPOROSIS IN GERIATRIC PATIENTS AND WOMEN TO DRIVE MARKET GROWTH

TABLE 31 EXAMPLES OF INJECTION PENS FOR OSTEOPOROSIS THERAPY

TABLE 32 INJECTION PENS MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.5 FERTILITY

7.5.1 DECREASE IN FERTILITY RATE HAS RESULTED IN THE INCREASED USE OF INJECTION PENS

TABLE 33 EXAMPLES OF INJECTION PENS FOR FERTILITY THERAPY

TABLE 34 INJECTION PENS MARKET FOR FERTILITY THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.6 CANCER

7.6.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH

TABLE 35 EXAMPLES OF INJECTION PENS FOR CANCER THERAPY

TABLE 36 INJECTION PENS MARKET FOR CANCER THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.7 AUTOIMMUNE DISEASES

7.7.1 DEVELOPMENTS IN THERAPIES AND DELIVERY DEVICES FOR THE TREATMENT OF MS TO BOOST THE MARKET GROWTH

TABLE 37 EXAMPLES OF INJECTION PENS FOR MULTIPLE SCLEROSIS AND

PSORIASIS THERAPY

TABLE 38 INJECTION PENS MARKET FOR AUTOIMMUNE DISEASE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)

7.8 OTHER THERAPIES

TABLE 39 INJECTION PENS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026 (USD MILLION)

8 INJECTION PENS MARKET, BY END USER

8.1 INTRODUCTION

TABLE 40 INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

8.2 HOME CARE SETTINGS

8.2.1 HOME CARE SETTINGS ARE THE LARGEST END USERS OF INJECTION PENS

TABLE 41 INJECTION PENS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION)

8.3 HOSPITALS & CLINICS

8.3.1 GROWING INCIDENCE OF NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES HAVE INCREASED THE DEMAND FOR INJECTION PENS

TABLE 42 INJECTION PENS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)

9 INJECTION PENS MARKET, BY REGION

9.1 INTRODUCTION

TABLE 43 INJECTION PENS MARKET, BY REGION, 2019–2026 (USD MILLION)

FIGURE 35 EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH

IN THE FORECAST PERIOD

9.2 NORTH AMERICA

FIGURE 36 NORTH AMERICA: INJECTION PENS MARKET SNAPSHOT

TABLE 44 INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 45 NORTH AMERICA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 46 NORTH AMERICA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 47 NORTH AMERICA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 48 NORTH AMERICA: INJECTION PENS MARKET, BY END USER,

2019–2026 (USD MILLION)

9.2.1 US

9.2.1.1 The US dominates the North American injection pens market

FIGURE 37 TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020)

TABLE 49 US: KEY MACROINDICATORS

TABLE 50 US: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 51 US: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 52 US: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 53 US: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.2.2 CANADA

9.2.2.1 Unfavorable regulatory processes in Canada to restrain the market growth

TABLE 54 CANADA: KEY MACROINDICATORS

TABLE 55 CANADA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 56 CANADA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 57 CANADA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 58 CANADA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3 EUROPE

TABLE 59 EUROPE: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 60 EUROPE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 61 EUROPE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 62 EUROPE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 63 EUROPE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.1 GERMANY

9.3.1.1 High diabetes expenditure and reimbursement for injection pens to drive the market in Germany

TABLE 64 GERMANY: KEY MACROINDICATORS

TABLE 65 GERMANY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 66 GERMANY: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 67 GERMANY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 68 GERMANY: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.2 FRANCE

9.3.2.1 Misuse of injection pens pose a threat to the growth of this market

TABLE 69 FRANCE: KEY MACROINDICATORS

TABLE 70 FRANCE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 71 FRANCE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 72 FRANCE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 73 FRANCE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.3 UK

9.3.3.1 NHS support and access to cost-effective injection pens are likely to drive the market in the UK

TABLE 74 UK: KEY MACROINDICATORS

TABLE 75 UK: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 76 UK: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 77 UK: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 78 UK: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.4 ITALY

9.3.4.1 Regional variation in terms of coverage and benefits to hinder the market growth

TABLE 79 ITALY: KEY MACROINDICATORS

TABLE 80 ITALY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 81 ITALY: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 82 ITALY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 83 ITALY: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.5 SPAIN

9.3.5.1 Supportive regulations mandating the use of safety injection pens to boost the growth of the Spanish market

TABLE 84 SPAIN: KEY MACROINDICATORS

TABLE 85 SPAIN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 86 SPAIN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 87 SPAIN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 88 SPAIN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.6 BENELUX

9.3.6.1 Increasing awareness about injection pen devices to drive market growth

TABLE 89 BENELUX: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 90 BENELUX: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 91 BENELUX: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 92 BENELUX: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.7 REST OF EUROPE

TABLE 93 ROE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 94 ROE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 95 ROE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 96 ROE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4 ASIA PACIFIC

FIGURE 38 ASIA PACIFIC: INJECTION PENS MARKET SNAPSHOT

TABLE 97 APAC: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 98 APAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 99 APAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 100 APAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 101 APAC: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.1 JAPAN

9.4.1.1 High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan

TABLE 102 JAPAN: KEY MACROINDICATORS

TABLE 103 JAPAN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 104 JAPAN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 105 JAPAN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 106 JAPAN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.2 CHINA

9.4.2.1 Large patient population and healthcare infrastructure improvements to drive the market growth in China

TABLE 107 CHINA: KEY MACROINDICATORS

TABLE 108 CHINA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 109 CHINA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 110 CHINA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 111 CHINA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.3 INDIA

9.4.3.1 Rising prevalence of obesity to drive market growth

TABLE 112 INDIA: KEY MACROINDICATORS

TABLE 113 INDIA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 114 INDIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 115 INDIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 116 INDIA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.4 SOUTHEAST ASIA

9.4.4.1 Growing awareness about diabetes to drive the adoption of injection pens

FIGURE 39 DIABETES PREVALENCE IN SOUTHEAST ASIA (2019)

FIGURE 40 HEALTHCARE EXPENDITURE (% OF GDP) IN SOUTHEAST ASIA (2018)

FIGURE 41 GERIATRIC POPULATION (% OF THE TOTAL POPULATION), 2019

TABLE 117 SOUTHEAST ASIA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 118 SOUTHEAST ASIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 119 SOUTHEAST ASIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 120 SOUTHEAST ASIA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.5 REST OF APAC

TABLE 121 ROAPAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 122 ROAPAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 123 ROAPAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 124 ROAPAC: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.5 LATIN AMERICA

TABLE 125 LATAM: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 126 LATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 127 LATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 128 LATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 129 LATAM: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.5.1 BRAZIL

9.5.1.1 Brazil dominates the injection pens market in Latin America

TABLE 130 BRAZIL: KEY MACROINDICATORS

TABLE 131 BRAZIL: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 132 BRAZIL: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD

MILLION)

TABLE 133 BRAZIL: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 134 BRAZIL: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.5.2 MEXICO

9.5.2.1 Increasing incidence of lifestyle-related disorders to drive market growth in Mexico

TABLE 135 MEXICO: KEY MACROINDICATORS

TABLE 136 MEXICO: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 137 MEXICO: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 138 MEXICO: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 139 MEXICO: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.5.3 REST OF LATIN AMERICA

FIGURE 42 HEALTH EXPENDITURE (% OF GDP) IN LATIN AMERICAN COUNTRIES, 2018

TABLE 140 ROLATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 141 ROLATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 142 ROLATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 143 ROLATAM: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.6 MIDDLE EAST & AFRICA

9.6.1 INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY TO SUPPORT MARKET GROWTH

TABLE 144 MEA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 145 MEA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)

TABLE 146 MEA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 147 MEA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 KEY PLAYER STRATEGIES

10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS

FIGURE 43 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE INJECTION PENS MARKET

10.4 MARKET SHARE ANALYSIS

FIGURE 44 INJECTION PENS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020

10.5 MARKET RANKING ANALYSIS OF OEM COMPANIES

FIGURE 45 INJECTION PENS MARKET RANKING, BY OEM COMPANY (2020)

10.6 COMPANY EVALUATION QUADRANT

10.6.1 STARS

10.6.2 EMERGING LEADERS

10.6.3 PERVASIVE PLAYERS

10.6.4 PARTICIPANTS

FIGURE 46 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT (2020)

10.7 COMPANY EVALUATION QUADRANT FOR START-UPS

10.7.1 PROGRESSIVE COMPANIES

10.7.2 DYNAMIC COMPANIES

10.7.3 STARTING BLOCKS

10.7.4 RESPONSIVE COMPANIES

FIGURE 47 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020)

10.8 COMPANY PRODUCT FOOTPRINT

TABLE 148 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY TYPE

TABLE 149 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY THERAPY

10.9 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE INJECTION PENS MARKET

TABLE 150 GEOGRAPHIC REVENUE MIX: INJECTION PENS MARKET (2020)

10.10 COMPETITIVE SCENARIO

10.10.1 PRODUCT LAUNCHES

TABLE 151 PRODUCT LAUNCHES (JANUARY 2018–SEPTEMBER 2021)

10.10.2 OTHER DEVELOPMENTS

TABLE 152 OTHER DEVELOPMENTS (JANUARY 2018–SEPTEMBER 2021)

11 COMPANY PROFILES

11.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View)*

11.1.1 NOVO NORDISK A/S

TABLE 153 NOVO NORDISK A/S: BUSINESS OVERVIEW

FIGURE 48 NOVO NORDISK A/S: COMPANY SNAPSHOT (2020)

11.1.2 BECTON, DICKINSON AND COMPANY

TABLE 154 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW

FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)

11.1.3 YPSOMED HOLDING AG

TABLE 155 YPSOMED HOLDING AG: BUSINESS OVERVIEW

FIGURE 50 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020)

11.1.4 SANOFI

TABLE 156 SANOFI: BUSINESS OVERVIEW

FIGURE 51 SANOFI: COMPANY SNAPSHOT (2020)

11.1.5 ELI LILLY AND COMPANY

TABLE 157 ELI LILLY AND COMPANY: BUSINESS OVERVIEW

FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)

11.1.6 MERCK KGAA

TABLE 158 MERCK KGAA: BUSINESS OVERVIEW

FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT (2020)

11.1.7 ASTRAZENECA

TABLE 159 ASTRAZENECA: BUSINESS OVERVIEW

FIGURE 54 ASTRAZENECA: COMPANY SNAPSHOT (2020)

11.1.8 F. HOFFMANN-LA ROCHE LTD.

TABLE 160 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW

FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)

11.1.9 OWEN MUMFORD

TABLE 161 OWEN MUMFORD: BUSINESS OVERVIEW

11.1.10 SULZER LTD.

TABLE 162 SULZER LTD.: BUSINESS OVERVIEW

11.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.

TABLE 163 SUN PHARMACEUTICAL INDUSTRIES LTD: BUSINESS OVERVIEW

FIGURE 56 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)

11.1.12 PFIZER

TABLE 164 PFIZER: BUSINESS OVERVIEW

FIGURE 57 PFIZER: COMPANY SNAPSHOT (2020)

11.1.13 BIOCON LTD.

TABLE 165 BIOCON LTD.: BUSINESS OVERVIEW

FIGURE 58 BIOCON LTD.: COMPANY SNAPSHOT (2020)

11.1.14 LUPIN LTD.

TABLE 166 LUPIN LTD.: BUSINESS OVERVIEW

FIGURE 59 LUPIN LTD.: COMPANY SNAPSHOT (2020)

11.1.15 WOCKHARDT LTD.

TABLE 167 WOCKHARDT LTD.: BUSINESS OVERVIEW

FIGURE 60 WOCKHARDT LTD.: COMPANY SNAPSHOT (2020)

11.1.16 APTARGROUP, INC.

TABLE 168 APTARGROUP, INC.: BUSINESS OVERVIEW

FIGURE 61 APTARGROUP, INC.: COMPANY SNAPSHOT (2020)

11.1.17 NOVARTIS AG

TABLE 169 NOVARTIS AG: BUSINESS OVERVIEW

FIGURE 62 NOVARTIS AG: COMPANY SNAPSHOT (2020)

11.1.18 GERRESHEIMER AG

TABLE 170 GERRESHEIMER AG: BUSINESS OVERVIEW

FIGURE 63 GERRESHEIMER AG: COMPANY SNAPSHOT (2020)

11.2 OTHER PLAYERS

11.2.1 SHAILY ENGINEERING PLASTICS LTD.

TABLE 171 SHAILY ENGINEERING PLASTICS LTD.: BUSINESS OVERVIEW

11.2.2 BESPAC EUROPE LTD.

TABLE 172 BESPAC EUROPE LTD.: BUSINESS OVERVIEW

11.2.3 SHL MEDICAL AG

TABLE 173 SHL MEDICAL AG: BUSINESS OVERVIEW

11.2.4 EMPERRA GMBH

TABLE 174 EMPERRA GMBH: BUSINESS OVERVIEW

11.2.5 NEMERA FRANCE SAS

TABLE 175 NEMERA FRANCE SAS: BUSINESS OVERVIEW

11.2.6 COMPANION MEDICAL, INC.

TABLE 176 COMPANION MEDICAL, INC.: BUSINESS OVERVIEW

11.2.7 JIANGSU DELFU MEDICAL DEVICE CO., LTD.

TABLE 177 JIANGSU DELFU MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW

* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

12 APPENDIX

12.1 DISCUSSION GUIDE

12.2 KNOWLEDGE STORE: MARKET SAND MARKETS' SUBSCRIPTION PORTAL

12.3 AVAILABLE CUSTOMIZATIONS

12.4 RELATED REPORTS

12.5 AUTHOR DETAILS

I would like to order

Product name: Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region - Global Forecast to 2026

Product link: <https://marketpublishers.com/r/I23AECD7662EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I23AECD7662EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970